Key Takeaways
- Patent Protection Secured: SOLASTA Bio has received its first patent grant for its peptide-based bioinsecticide technology, with additional patents expected.
- Regulatory Breakthrough: The U.S. Environmental Protection Agency (EPA) has designated SOLASTA Bio’s lead peptide candidates as biochemical-like, significantly streamlining regulatory approval.
- Targeted Pest Control: The company’s insect neuropeptide-based bioinsecticides kill harmful pests like aphids while being safe for pollinators and the environment.
- Accelerated Commercial Pathway: The EPA classification enables SOLASTA Bio to bypass traditional insecticide registration, reducing time and costs to market.
- Investor Confidence: Following an oversubscribed $14M Series A funding round in 2024, the company has attracted investment from Forbion BioEconomy Fund, FMC Ventures, and Corteva Catalyst.
SOLASTA Bio Secures Patent Grant and EPA Approval for Green Insecticides
SOLASTA Bio, a leader in next-generation green insecticides, has reached a major milestone in its path to regulatory approval and commercialization. The company, known for its nature-inspired, small peptide-based insect control agents, has secured its first patent grant and received a favorable classification from the U.S. Environmental Protection Agency (EPA), significantly advancing its commercial strategy.
Strengthening Intellectual Property with Patent Grants
SOLASTA Bio’s patent allowances from both the U.S. and European Patent Offices cover its novel peptide candidates, reinforcing its intellectual property (IP) position and securing its competitive advantage in the biological crop protection market.
These patents provide critical protection as the company advances its peptide-based bioinsecticides toward product development and full-scale commercialization.
Regulatory Breakthrough with EPA Biochemical-Like Classification
In a parallel development, SOLASTA Bio’s lead peptide candidates have been designated as biochemical-like by the U.S. EPA. This classification allows the company to bypass conventional insecticide registration pathways, significantly reducing the time and cost of market entry.
Shireen Davies, CEO & Co-Founder of SOLASTA Bio, commented: “These developments represent a major inflection point for SOLASTA Bio. The combination of strong patent protection and a more efficient regulatory pathway positions us exceptionally well to advance our product development and reach full commercialization within a few years. Our technology has the potential to transform the global crop protection market, and we are now one giant stride closer to realizing that vision.”
Next-Generation Bioinsecticides: Safe for Pollinators, Effective Against Pests
SOLASTA Bio’s bioinsecticides work by disrupting insect neuropeptides, which regulate essential physiological functions in target pests like aphids. This precision-targeted approach ensures:
- Effective pest control without harming pollinators such as bees.
- Environmentally friendly solutions to replace conventional chemical insecticides.
- Sustainable alternatives that align with the shift toward biological crop protection.
SOLASTA Bio Strong Investor Backing and Industry Momentum
These latest achievements follow the company’s oversubscribed $14 million Series A funding round in September 2024. The round attracted investments from leading agricultural and life sciences investors, including:
- Forbion BioEconomy Fund
- FMC Ventures
- Corteva Catalyst
